Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

413 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project.
Voso MT, Guarnera L, Lehmann S, Döhner K, Döhner H, Platzbecker U, Russell NH, Dillon RJ, Thomas I, Ossenkoppele GJ, Haferlach T, Vignetti M, La Sala E, Piciocchi A, Fazi P, Villaverde Ramiro Á, Tur Giménez L, Gurnari C, Bullinger L, Hernandez JM. Voso MT, et al. Among authors: ossenkoppele gj. Blood. 2024 Nov 6:blood.2024026186. doi: 10.1182/blood.2024026186. Online ahead of print. Blood. 2024. PMID: 39504485
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.
Huls G, Chitu DA, Tick L, Boersma R, Breems D, Herbers A, Klein SK, de Jonge S, Westerweel PE, Cruijsen M, Hoogendoorn M, Cuijpers M, Deeren D, Bailly B, Visser O, van Rhenen A, Posthuma EFM, Valk PJM, Cloos J, Ammatuna E, Refos JM, Fakkert R, Löwenberg B, Ossenkoppele GJ. Huls G, et al. Among authors: ossenkoppele gj. Ann Hematol. 2024 Oct 5. doi: 10.1007/s00277-024-06033-y. Online ahead of print. Ann Hematol. 2024. PMID: 39367118
Risk Stratification in Older Intensively Treated Patients With AML.
Versluis J, Metzner M, Wang A, Gradowska P, Thomas A, Jakobsen NA, Kennedy A, Moore R, Boertjes E, Vonk CM, Kavelaars FG, Rijken M, Gilkes A, Schwab C, Beverloo HB, Manz M, Visser O, Van Elssen CHMJ, de Weerdt O, Tick LW, Biemond BJ, Vekemans MC, Freeman SD, Harrison CJ, Cook JA, Dennis M, Knapper S, Thomas I, Craddock C, Ossenkoppele GJ, Löwenberg B, Russell N, Valk PJM, Vyas P. Versluis J, et al. Among authors: ossenkoppele gj. J Clin Oncol. 2024 Dec;42(34):4084-4094. doi: 10.1200/JCO.23.02631. Epub 2024 Sep 4. J Clin Oncol. 2024. PMID: 39231389 Free PMC article.
The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells.
Reuvekamp T, Janssen LLG, Ngai LL, Carbaat-Ham J, den Hartog D, Scholten WJ, Kelder A, Hanekamp D, Wensink E, van Gils N, Gradowska P, Löwenberg B, Ossenkoppele GJ, van de Loosdrecht AA, Westers TM, Smit L, Bachas C, Cloos J. Reuvekamp T, et al. Among authors: ossenkoppele gj. Cytometry B Clin Cytom. 2024 Aug 23. doi: 10.1002/cyto.b.22201. Online ahead of print. Cytometry B Clin Cytom. 2024. PMID: 39177948
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML).
Rodríguez-Arbolí E, Othus M, Freeman SD, Buccisano F, Ngai LL, Thomas I, Palmieri R, Cloos J, Johnson S, Meddi E, Russell NH, Venditti A, Gradowska P, Ossenkoppele GJ, Löwenberg B, Walter RB. Rodríguez-Arbolí E, et al. Among authors: ossenkoppele gj. Leukemia. 2024 Oct;38(10):2266-2269. doi: 10.1038/s41375-024-02378-5. Epub 2024 Aug 21. Leukemia. 2024. PMID: 39169114 No abstract available.
Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial.
van der Maas NG, Versluis J, Nasserinejad K, van Rosmalen J, Pabst T, Maertens J, Breems D, Manz M, Cloos J, Ossenkoppele GJ, Floisand Y, Gradowska P, Löwenberg B, Huls G, Postmus D, Pignatti F, Cornelissen JJ. van der Maas NG, et al. Among authors: ossenkoppele gj. Blood Cancer J. 2024 Mar 27;14(1):56. doi: 10.1038/s41408-024-01037-3. Blood Cancer J. 2024. PMID: 38538587 Free PMC article.
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.
van de Loosdrecht AA, Cremers EMP, Alhan C, Duetz C, In 't Hout FEM, Visser-Wisselaar HA, Chitu DA, Verbrugge A, Cunha SM, Ossenkoppele GJ, Janssen JJWM, Klein SK, Vellenga E, Huls GA, Muus P, Langemeijer SMC, de Greef GE, Te Boekhorst PAW, Raaijmakers MHG, van Marwijk Kooy M, Legdeur MC, Wegman JJ, Deenik W, de Weerdt O, van Maanen-Lamme TM, Jobse P, van Kampen RJW, Beeker A, Wijermans PW, Biemond BJ, Tanis BC, van Esser JWJ, Schaar CG, Noordzij-Nooteboom HS, Jacobs EMG, de Graaf AO, Jongen-Lavrencic M, Stevens-Kroef MJPL, Westers TM, Jansen JH. van de Loosdrecht AA, et al. Among authors: ossenkoppele gj. Leukemia. 2024 Apr;38(4):840-850. doi: 10.1038/s41375-024-02161-6. Epub 2024 Jan 31. Leukemia. 2024. PMID: 38297135 Free PMC article. Clinical Trial.
Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia.
Tettero JM, Heidinga ME, Mocking TR, Fransen G, Kelder A, Scholten WJ, Snel AN, Ngai LL, Bachas C, van de Loosdrecht AA, Ossenkoppele GJ, de Leeuw DC, Cloos J, Janssen JJWM. Tettero JM, et al. Among authors: ossenkoppele gj. Leukemia. 2024 Mar;38(3):630-639. doi: 10.1038/s41375-024-02158-1. Epub 2024 Jan 25. Leukemia. 2024. PMID: 38272991 Free PMC article.
Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML.
Tettero JM, Buisman Y, Ngai LL, Bachas C, Gjertsen BT, Kelder A, van de Loosdrecht AA, Manz MG, Pabst T, Scholten W, Ossenkoppele GJ, Cloos J, de Leeuw DC. Tettero JM, et al. Among authors: ossenkoppele gj. Hemasphere. 2023 Nov 21;7(12):e981. doi: 10.1097/HS9.0000000000000981. eCollection 2023 Dec. Hemasphere. 2023. PMID: 38026789 Free PMC article. No abstract available.
413 results